Biography:James L. Gulley

From HandWiki
Revision as of 05:46, 9 February 2024 by John Stpola (talk | contribs) (over-write)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
James L. Gulley
EducationLoma Linda University, Emory University, National Cancer Institute
Medical career
ProfessionMedical oncologist
InstitutionsNational Cancer Institute
Sub-specialtiesgenitourinary oncology, immunotherapy
Researchcancer research
Website

James L. Gulley is an American cancer researcher and the Director of the Medical Oncology Service at National Cancer Institute.[1]

Early life and education

He graduated from Loma Linda University, California [2] and his M.D./Ph.D. Medical Scientist Training Program, at National Institutes of Health (NIH) and his dissertation on tumor immunology.[3] Later, Gulley did his residency in internal medicine at Emory University in 1998, followed by a medical oncology fellowship at the NCI.[4]

Research and career

Gulley did his research in immunotherapy for prostate cancer. His studies involved the use of cancer vaccine[5] and immune checkpoint inhibitors or other strategies to enhance vaccine-mediated killing.[6] Since 1999, he ran clinical trials at the NCI,[7] serving as Principal Investigator or an Associate Investigator on approximately 40 trials. He is also running studies on cancer patients.[8][9][10]

Publications

He published over 250 research papers & book chapters across leading journals.[11][12] Some of his notable publications are listed below:

  • Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer[13]
  • Androgen deprivation therapy for prostate cancer[14]
  • Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer[15]
  • Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer[16]
  • Phase I study of sequential vaccinations with fowlpox-CEA (6D)-TRICOM alone and sequentially with vaccinia-CEA (6D)-TRICOM[17]
  • A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.[18]
  • Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer[19]
  • Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial[20]

FDA approval

At the 2010 ASCO meeting Gulley and his group reported on the use of Ipilimumab with a vector-based vaccine for treating advanced prostate cancer. This phase I trial using PSA-TRICOM with Ipilimumab (Ipi) showed promise for Overall Survival (OS).[21] Ipi is used in melanoma vaccine clinical trials.[22] It was approved by the FDA in March 2011.[23][24][25][26]

Awards

  • He received Presidential Early Career Award for Science and Engineering “For randomized, controlled studies using novel, recombinant vaccines to reduce the progression of prostate and other cancers and increase survival.” [27][28]
  • He received Federal Laboratory Consortium Excellence in Federal Technology Transfer Award, a national award for “Development of first immunotherapy to treat chordoma, a rare bone cancer.”[29]

References

  1. ↑ "Medical Oncology Service" (in en). 2016-02-09. https://ccr.cancer.gov/about/office-of-the-clinical-director/medical-oncology-service. 
  2. ↑ "James L. Gulley, M.D., Ph.D." (in en). 2014-08-12. https://ccr.cancer.gov/Genitourinary-Malignancies-Branch/james-l-gulley. 
  3. ↑ "Principal Investigators" (in en). https://irp.nih.gov/pi/james-gulley. 
  4. ↑ "Medical Oncology Web - FELLOWSHIP". Medicaloncology.cancer.gov. http://medicaloncology.cancer.gov/index.php/fellowship/index.htm. Retrieved 2010-07-14. 
  5. ↑ Gulley, James L.; Arlen, Philip M.; Schlom, Jeffrey (2007-07-01). "Cancer Vaccines: Moving Beyond Current Paradigms" (in en). Clinical Cancer Research 13 (13): 3776–3782. doi:10.1158/1078-0432.CCR-07-0588. ISSN 1078-0432. PMID 17606707. 
  6. ↑ "James L. Gulley, MD, PhD, on Prostate Cancer: Expanding Immunotherapy Options - The ASCO Post". https://ascopost.com/videos/2018-asco-sitc-clinical-immuno-oncology-symposium/james-l-gulley-md-phd-on-prostate-cancer-expanding-immunotherapy-options/. 
  7. ↑ Gulley, James (2015-02-23). "James Gulley" (in en). https://irp.nih.gov/blog/author/james-gulley. 
  8. ↑ "Clinical Trials at NIH: Health Care Professionals: Investigator Profiles: James L. Gulley, M.D". Bethesdatrials.cancer.gov. Archived from the original on 2010-05-27. https://web.archive.org/web/20100527113440/http://bethesdatrials.cancer.gov/investigator-profiles/gulley/default.asp. Retrieved 2010-07-14. 
  9. ↑ "Clinical Trials at NIH: Health Care Professionals: Investigator Profiles: James L. Gulley, M.D.". 2010-05-27. http://bethesdatrials.cancer.gov/investigator-profiles/gulley/default.asp. 
  10. ↑ "Genitourinary Malignancies Branch Clinical Trials" (in en). https://ccr.cancer.gov/genitourinary-malignancies-branch/clinical-trials. 
  11. ↑ "My Bibliography James Gulley's Bibliography". https://www.ncbi.nlm.nih.gov/sites/myncbi/james.gulley.1/bibliography/47943666/public/?sort=date&direction=ascending. 
  12. ↑ "Center for Cancer Research - Staff Pages". Ccr.cancer.gov. Archived from the original on 2010-05-27. https://web.archive.org/web/20100527145339/http://ccr.cancer.gov/staff/cv.asp?profileid=5686. Retrieved 2010-07-14. 
  13. ↑ Kantoff, Philip W.; Schuetz, Thomas J.; Blumenstein, Brent A.; Glode, L. Michael; Bilhartz, David L.; Wyand, Michael; Manson, Kelledy; Panicali, Dennis L. et al. (2010-03-01). "Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer". Journal of Clinical Oncology 28 (7): 1099–1105. doi:10.1200/JCO.2009.25.0597. ISSN 1527-7755. PMID 20100959. 
  14. ↑ Dahut, William L.; Gulley, James L.; Sharifi, Nima (2005-07-13). "Androgen Deprivation Therapy for Prostate Cancer" (in en). JAMA 294 (2): 238–244. doi:10.1001/jama.294.2.238. ISSN 0098-7484. PMID 16014598. 
  15. ↑ Dahut, William L.; Gulley, James L.; Arlen, Philip M.; Liu, Yinong; Fedenko, Katherine M.; Steinberg, Seth M.; Wright, John J.; Parnes, Howard et al. (2004-07-01). "Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer". Journal of Clinical Oncology 22 (13): 2532–2539. doi:10.1200/JCO.2004.05.074. ISSN 0732-183X. PMID 15226321. 
  16. ↑ Gulley, James L.; Arlen, Philip M.; Bastian, Anne; Morin, Steven; Marte, Jennifer; Beetham, Patricia; Tsang, Kwong-Yok; Yokokawa, Junko et al. (2005-05-01). "Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer". Clinical Cancer Research 11 (9): 3353–3362. doi:10.1158/1078-0432.CCR-04-2062. ISSN 1078-0432. PMID 15867235. 
  17. ↑ Marshall, John L.; Gulley, James L.; Arlen, Philip M.; Beetham, Patricia K.; Tsang, Kwong-Yok; Slack, Rebecca; Hodge, James W.; Doren, Sandra et al. (2005-02-01). "Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas". Journal of Clinical Oncology 23 (4): 720–731. doi:10.1200/JCO.2005.10.206. ISSN 0732-183X. PMID 15613691. 
  18. ↑ Arlen, Philip M.; Gulley, James L.; Parker, Catherine; Skarupa, Lisa; Pazdur, Mary; Panicali, Dennis; Beetham, Patricia; Tsang, Kwong Y. et al. (2006-02-15). "A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer". Clinical Cancer Research 12 (4): 1260–1269. doi:10.1158/1078-0432.CCR-05-2059. ISSN 1078-0432. PMID 16489082. 
  19. ↑ Gulley, James L.; Arlen, Philip M.; Madan, Ravi A.; Tsang, Kwong-Yok; Pazdur, Mary P.; Skarupa, Lisa; Jones, Jacquin L.; Poole, Diane J. et al. (2010). "Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer". Cancer Immunology, Immunotherapy 59 (5): 663–674. doi:10.1007/s00262-009-0782-8. ISSN 1432-0851. PMID 19890632. 
  20. ↑ Madan, Ravi A.; Mohebtash, Mahsa; Arlen, Philip M.; Vergati, Matteo; Rauckhorst, Myrna; Steinberg, Seth M.; Tsang, Kwong Y.; Poole, Diane J. et al. (2012). "Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial". The Lancet. Oncology 13 (5): 501–508. doi:10.1016/S1470-2045(12)70006-2. ISSN 1474-5488. PMID 22326924. 
  21. ↑ Madan, Ravi A.; Mohebtash, Mahsa; Arlen, Philip M.; Vergati, Matteo; Rauckhorst, Myrna; Steinberg, Seth M.; Tsang, Kwong Y.; Poole, Diane J. et al. (2012). "Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial". The Lancet. Oncology 13 (5): 501–508. doi:10.1016/S1470-2045(12)70006-2. ISSN 1474-5488. PMID 22326924. 
  22. ↑ Sarnaik, A. A.; Yu, B.; Yu, D.; Morelli, D.; Hall, M.; Bogle, D.; Yan, L.; Targan, S. et al. (2010). "Extended Dose Ipilimumab with a Peptide Vaccine: Immune Correlates Associated with Clinical Benefit in Patients with Resected High-Risk Stage IIIc/IV Melanoma". Clinical Cancer Research 17 (4): 896–906. doi:10.1158/1078-0432.CCR-10-2463. PMID 21106722. 
  23. ↑ Hoos, Axel; Ibrahim, Ramy; Korman, Alan; Abdallah, Kald; Berman, David; Shahabi, Vafa; Chin, Kevin; Canetta, Renzo et al. (2010). "Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy". Seminars in Oncology 37 (5): 533–46. doi:10.1053/j.seminoncol.2010.09.015. PMID 21074069. 
  24. ↑ "Experimental Drug Improves Survival in Advanced Melanoma - National Cancer Institute". http://www.cancer.gov/clinicaltrials/results/ipilimumab0610. 
  25. ↑ Madan, Ravi A.; Mohebtash, Mahsa; Arlen, Philip M.; Vergati, Matteo; Rauckhorst, Myrna; Steinberg, Seth M.; Tsang, Kwong Y.; Poole, Diane J. et al. (2012). "Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial". The Lancet. Oncology 13 (5): 501–508. doi:10.1016/S1470-2045(12)70006-2. ISSN 1474-5488. PMID 22326924. 
  26. ↑ Schlom, Jeffrey; Gulley, James L. (2018-12-04). "Vaccines as an Integral Component of Cancer Immunotherapy". JAMA 320 (21): 2195–2196. doi:10.1001/jama.2018.9511. ISSN 1538-3598. PMID 30419097. 
  27. ↑ "President Obama Honors Outstanding Early-Career Scientists" (in en). 2011-09-26. https://obamawhitehouse.archives.gov/the-press-office/2011/09/26/president-obama-honors-outstanding-early-career-scientists. 
  28. ↑ "CCR Connections (News) - An Early Career Off to a Stellar Start". https://home.ccr.cancer.gov/Connections/2011/Vol5_No2/news_6.asp. 
  29. ↑ "Recent CCR Awards" (in en). 2016-06-21. https://ccr.cancer.gov/connections/news/8. 

External links

{{Navbox 

| name = Tumors
| title = Overview of tumors, cancer and oncology (C00–D48, 140–239)
| state = autocollapse
| listclass = hlist

| group1 = Conditions

| list1 =

Benign tumors
Malignant progression
Topography
Histology
Other
| group2 = Staging/grading
| list2 =

| group3 = Carcinogenesis
| list3 =

| group4 = Misc.
| list4 =

}}



Retrieved from "https://handwiki.org/wiki/index.php?title=Biography:James_L._Gulley&oldid=3441042"